Top Suppliers:I want be here



210755-45-6

210755-45-6 structure
210755-45-6 structure
  • Name: CP-471474
  • Chemical Name: 2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-N-hydroxy-2-methylpropanamide
  • CAS Number: 210755-45-6
  • Molecular Formula: C16H17FN2O5S
  • Molecular Weight: 368.38000
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease MMP
  • Create Date: 2016-12-21 20:28:51
  • Modify Date: 2025-08-29 22:05:41
  • CP-471474 is an orally active and pan MMP inhibitor, with IC50 values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively[1][2].

Name 2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-N-hydroxy-2-methylpropanamide
Synonyms 2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydrox y-2-methylpropanamide PF-1626077
HMS3262O11
UNII-96U47H947L
Description CP-471474 is an orally active and pan MMP inhibitor, with IC50 values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively[1][2].
Related Catalog
Target

MMP-2:0.7 nM (IC50)

MMP-13:0.9 nM (IC50)

MMP-9:13 nM (IC50)

MMP-3:16 nM (IC50)

MMP-1:1170 nM (IC50)

In Vivo CP-471474 plasma levels following subcutaneous injection are 2,020 ng/mL (1 h postdose) to 160 ng/mL (6 h postdose)[2]. CP-471,474 significantly reduces both the extent and severity of inflammation at 2 months. At 4 months, a spontaneous reduction of the inflammatory response is observed in both treated and untreated animals, and consequently no difference is observed between both[2]. CP-471474 significantly decreases the destructive lesions mainly at 2 months and also at 4 months[2]. Animal Model: Guinea pigs weighing 400 to 450 g (COPD)[2]. Dosage: 20 mg/kg (also supplemented daily by the diet (200 mg/200 g powdered chow)). Administration: Subcutaneously (in 20% ethanol/80% polyethylene glycol), once a day during the entire course. Result: Lungs derived from smoking animals treated with the compound demonstrated a statistically significant reduction in the destructive lesions. Showed an increase of both pro–MMP-9 and its active form (lanes 5 to 8) as compared with control animals.
References

[1]. L E Rohde, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999 Jun 15;99(23):3063-70.

[2]. Moisés Selman, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest. 2003 May;123(5):1633-41.

Molecular Formula C16H17FN2O5S
Molecular Weight 368.38000
Exact Mass 368.08400
PSA 116.60000
LogP 4.49230
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.